A novel anti-androgen candidate galeterone acts by targeting USP12, a deubiquitinating enzyme that controls prostate cancer growth and survival. (December 2016) - McClurg, U.; Dransfield, D.; Namdev, N.; Jacoby, D.; Chit, N.; Nakjang, S.; Edwards, J.; McCracken, S.; Robson, C.